IntelGenx Technologies (IGXT) Given a $2.00 Price Target at HC Wainwright

HC Wainwright set a $2.00 target price on IntelGenx Technologies (OTCMKTS:IGXT) in a report issued on Friday. The firm currently has a buy rating on the stock.

IGXT has been the subject of several other research reports. Zacks Investment Research cut shares of IntelGenx Technologies from a buy rating to a hold rating in a research note on Wednesday, October 17th. Maxim Group restated a buy rating and issued a $2.00 target price on shares of IntelGenx Technologies in a research note on Friday. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $1.58.

OTCMKTS:IGXT traded down $0.02 during trading hours on Friday, reaching $0.58. 450,010 shares of the company’s stock were exchanged, compared to its average volume of 768,850. The stock has a market cap of $46.88 million, a P/E ratio of -14.39 and a beta of 1.42. The company has a debt-to-equity ratio of 4.56, a current ratio of 1.90 and a quick ratio of 1.90. IntelGenx Technologies has a 1-year low of $0.55 and a 1-year high of $1.83.

IntelGenx Technologies (OTCMKTS:IGXT) last released its earnings results on Thursday, August 9th. The company reported ($0.04) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). IntelGenx Technologies had a negative net margin of 202.88% and a negative return on equity of 214.48%. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.10 million. Sell-side analysts expect that IntelGenx Technologies will post -0.14 EPS for the current fiscal year.

IntelGenx Technologies Company Profile

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat cognitive impairment and Alzheimer's disease.

Further Reading: What does relative strength index mean?

Receive News & Ratings for IntelGenx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelGenx Technologies and related companies with's FREE daily email newsletter.

Leave a Reply